---
title: "CAMP4 Reports Net Loss Of $18 Mln In Q1; Advances CMP-002 For SYNGAP1-related Disorders"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285745839.md"
description: "CAMP4 Therapeutics Corporation reported a net loss of $18.33 million in Q1 2026, compared to a loss of $12.43 million in Q1 2025. R&D expenses remained stable at $10.16 million. The company has $99.21 million in cash and equivalents. CAMP4 is advancing CMP-002 for SYNGAP1-related disorders, with a Phase 1/2 trial expected in late 2026 and orphan drug designations from the EMA and FDA. The stock is currently trading at $4.27, down 1.50%."
datetime: "2026-05-08T15:00:27.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285745839.md)
  - [en](https://longbridge.com/en/news/285745839.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285745839.md)
---

# CAMP4 Reports Net Loss Of $18 Mln In Q1; Advances CMP-002 For SYNGAP1-related Disorders

(RTTNews) - CAMP4 Therapeutics Corporation (CAMP), a clinical-stage biopharmaceutical company, on Thursday released its first-quarter financial results and provided various business highlights.

The company specializes in developing RNA-targeted therapies to upregulate gene expression to effectively treat genetic diseases.

Q1 2026:

The company reported a net loss of $18.33 million, or $0.32 per share, in Q1 2026, while in the same period of 2025, the net loss was $12.43 million, or $0.62 per share.

Research and development expenses (R&D) were $10.16 million, relatively stable compared to $10.15 million in the previous year.

Cash, cash equivalents, and marketable securities on March 31, 2026, amounted to $99.21 million.

Business Updates:

CAMP4 submitted a regulatory filing in Australia to enable a Phase 1/2 clinical trial for CMP-002 in the second half of 2026. CMP-002, a first-in-class treatment for SYNGAP1-related disorders, was also granted an orphan drug designation by the European Medicines Agency (EMA) and filed to receive an orphan drug designation from the FDA.

The company also began a collaboration with CURE SYNGAP for the ProMMis study to determine the natural history of SYNGAP1-related disorders and to develop effective therapies.

A preprint of a pioneering study was submitted, outlining regRNA capture sequencing to create the largest catalog of regRNAs.

CAMP is currently trading at $4.27, down 1.50%.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

### Related Stocks

- [CAMP.US](https://longbridge.com/en/quote/CAMP.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [NDAQ.US](https://longbridge.com/en/quote/NDAQ.US.md)

## Related News & Research

- [Pharma giants commit $500B to US amid tariff threat](https://longbridge.com/en/news/289866895.md)
- [The wrong prescription for drug affordability](https://longbridge.com/en/news/289929515.md)
- [CAMP4 Therapeutics Corporation (CAMP) Receives a New Rating from Chardan Capital](https://longbridge.com/en/news/289275111.md)
- [Camp4 Therapeutics Earnings Review: Q4 Summary](https://longbridge.com/en/news/277987792.md)
- [This Exxon Mobil Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday](https://longbridge.com/en/news/289915978.md)